[New agents for the treatment of hepatitis C].

Abstract

The current treatment of Chronic Hepatitis C (CHC) is based on the combination of peginterferon alpha 2a or 2b and ribavirin. This treatment achieves Sustained Virological Response (SVR) rates in more than 50% of the patients. The SVR rates are higher in genotype 2 and 3 patients than in genotype 1, which account for more than 50%. For this reason, the… (More)
DOI: 10.1016/j.eimc.2011.09.012

Topics

3 Figures and Tables

Slides referencing similar topics